Propranolol Hydrochloride Extended-Release Capsules, USP, 60mg

  • Due to potential metal contamination
  • Company: Breckenridge Pharmaceutical, Inc.
  • Drugs
  • FDA
  • November 16, 2026

Product details

  • Propranolol Hydrochloride Extended-Release Capsules, USP, 60mg

Company announcement

Breckenridge Pharmaceutical, Inc. is voluntarily recalling one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, due to potential metal contamination.

The product was distributed nationwide to wholesalers and pharmacies between October 26, 2026, and November 04, 2026.

No adverse events related to this recall have been reported to date.

Risk:

Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine. The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market. To date, Breckenridge is not aware of any adverse events assessed to be related to this recall.

Impacted states: Nationwide

Products:

- Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg (UPC code(s): 5199181701)

Contact

For more information, call 1-855-736-0807.

View the original FDA notice

Browse all recalls

Related recalls